Cargando…

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients

Analysis of circulating cell-free DNA (cfDNA) derived from peripheral blood (“liquid biopsy”) is an attractive alternative to identify non-small cell lung cancer (NSCLC) patients with the EGFR T790M mutation eligible for 3rd generation tyrosine kinase inhibitor therapy. We evaluated two PCR-based ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollbrecht, Claudia, Lehmann, Annika, Lenze, Dido, Hummel, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915090/ https://www.ncbi.nlm.nih.gov/pubmed/29719623 http://dx.doi.org/10.18632/oncotarget.24908

Ejemplares similares

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR
por: Silveira, Catarina, et al.
Publicado: (2021)

Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs
por: Ma, Li, et al.
Publicado: (2021)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
por: Oya, Yuko, et al.
Publicado: (2021)

A new method to prevent carry-over contaminations in two-step PCR NGS library preparations
por: Seitz, Volkhard, et al.
Publicado: (2015)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
por: Watanabe, Kana, et al.
Publicado: (2023)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Zou, Bin, et al.
Publicado: (2017)

Liquid biopsy for T790M mutation detection: A ray of hope?
por: Mohan, Anant, et al.
Publicado: (2020)

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
por: Vollbrecht, Claudia, et al.
Publicado: (2018)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
por: Remon, Jordi, et al.
Publicado: (2020)

Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients
por: Sesé, Marta, et al.
Publicado: (2019)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

The efficacy of T790M mutation testing in liquid biopsy—Real clinic data
por: Krawczyk, Paweł, et al.
Publicado: (2022)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
por: Chua, Khi Pin, et al.
Publicado: (2021)

Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
por: Filipits, Martin, et al.
Publicado: (2023)

A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies
por: Jensen, Steffen Grann, et al.
Publicado: (2021)

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
por: He, Changlong, et al.
Publicado: (2021)

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
por: Li, Yi-Ze, et al.
Publicado: (2023)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
por: Demuth, Christina, et al.
Publicado: (2018)

Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays
por: Hallermayr, Ariane, et al.
Publicado: (2023)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in EGFR-Mutated NSCLC
por: Barr, Martin P., et al.
Publicado: (2022)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations
por: Li, Xiao-Feng, et al.
Publicado: (2020)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR(L858R/T790M) Mutations
por: Hassanin, Moamen A., et al.
Publicado: (2022)

Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
por: Mambetsariev, Isa, et al.
Publicado: (2018)

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
por: Vollbrecht, Claudia, et al.
Publicado: (2022)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC
por: Kim, In Ae, et al.
Publicado: (2022)

EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience
por: Dal Maso, Alessandro, et al.
Publicado: (2022)

Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)

Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation
por: Zhang, Xuehui, et al.
Publicado: (2021)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
por: Yamada, Teppei, et al.
Publicado: (2013)

Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients
por: Simarro, Javier, et al.
Publicado: (2022)

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
por: Zheng, D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_umqij1g2kvo9kig1pv9pkgsqat